Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of California San Diego
Headquarters: La Jolla, CA, United States of America
Website: http://ucsd.edu
Year Founded: 1960
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 13, 2024
Discovery & Translation
Science Spotlight: How extrachromosomal DNA drives cancer
BioCentury’s roundup of translational innovation features two trios of papers: one on genetic control of cancer and the other on MASLD markers
BioCentury | Nov 8, 2024
Deals
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger
Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ
BioCentury | Oct 3, 2024
Discovery & Translation
Type 2 cytokines for durable cancer remission, drugging GTPases: BioCentury’s Science Spotlight
BioCentury’s roundup of translational innovations
BioCentury | Jul 3, 2024
Discovery & Translation
Science Spotlight: Epigenetic editor for brain prion silencing, Mopac’s oral biologics and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 26, 2024
Emerging Company Profile
Visgenx: Taking retinal gene therapy beyond rare disease
First program delivers an enzyme involved in the fatty acid synthesis pathway for patients with dry AMD
BioCentury | Apr 3, 2024
Emerging Company Profile
Calluna: targeting upstream innate immune amplifiers
The Oslo-based biotech is developing a S100A4 inhibitor that it believes could be first in class in fibrotic, immunology settings
BioCentury | Mar 12, 2024
Discovery & Translation
Distillery spotlight: new mitochondrial mechanisms from academia
Correcting mitochondrial dynamics, metabolic control of pathogenic or therapeutic cells emerge among translational innovations in BioCentury’s survey of 2023 publications
BioCentury | Mar 8, 2024
Discovery & Translation
Distillery spotlight: new ubiquitin-modulating mechanisms from academia
Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature
BioCentury | Mar 5, 2024
Discovery & Translation
Distillery spotlight: new Alzheimer’s mechanisms from academia
BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease
Items per page:
1 - 10 of 619